Pablo Corral/LinkedIn
Oct 29, 2025, 07:39
Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction
- Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
- Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
- Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
- Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
- Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.
The real challenge is no longer how low can we go, but how many actually get there.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda